{"doi":"10.1016/j.psychres.2020.113409","title":"Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond","abstract":null,"journal":"Psychiatry Research","year":2020,"id":630930,"datarank":0.6591673732008659,"base_score":4.394449154672439,"endowment":4.394449154672439,"self_citation_contribution":0.6591673732008659,"citation_network_contribution":0.0,"self_endowment_contribution":0.6591673732008659,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":80,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1634796,"name":"Maju Mathew Koola","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond","abstract":"Alzheimer's disease (AD) is the most prevalent form of dementia in the elderly population worldwide. Despite the major unmet clinical need, no new medications for the treatment of AD have been approved since 2003. Galantamine is an acetylcholinesterase inhibitor that is also a positive allosteric modulator at the α4β2 and α7nACh receptors. Memantine is an N-methyl-d-aspartate receptor modulator/agonist. Both galantamine and memantine are FDA-approved medications for the treatment of AD. The objective of this review is to highlight the potential of the galantamine-memantine combination to conduct randomized controlled trials (RCTs) in AD. Several studies have shown the combination to be effective. Neurodegenerative diseases involve multiple pathologies; therefore, combination treatment appears to be a rational approach. Although underutilized, the galantamine-memantine combination is the standard of care in the treatment of AD. Positive RCTs with the combination with concurrent improvement in symptoms and biomarkers may lead to FDA approval, which may lead to greater utilization of this combination in clinical practice.","is_dataset_classified":null,"base_score":4.394449154672439,"endowment":4.394449154672439,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32829072","pmcid":null,"openalex_id":"https://openalex.org/W3074538089","authors":[],"funders":[],"total_grants":0,"fwci":6.894,"citation_percentile":0.97930878,"influential_citations":0,"citation_trend":[{"year":2020,"count":7},{"year":2021,"count":11},{"year":2022,"count":16},{"year":2023,"count":14},{"year":2024,"count":16},{"year":2025,"count":8},{"year":2026,"count":8}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://doi.org/10.1016/j.psychres.2020.113409","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32829072","host_type":"repository"}],"fields_of_study":["Cholinesterase and Neurodegenerative Diseases","Chemical synthesis and alkaloids","Nicotinic Acetylcholine Receptors Study","Alzheimer Disease","Cholinesterase Inhibitors","Drug Therapy, Combination","Excitatory Amino Acid Antagonists","Galantamine","Humans","Memantine","Nootropic Agents","Randomized Controlled Trials as Topic","Receptors, N-Methyl-D-Aspartate"],"mesh_terms":["Alzheimer Disease","Cholinesterase Inhibitors","Drug Therapy, Combination","Galantamine","Humans","Memantine","Randomized Controlled Trials as Topic","Receptors, N-Methyl-D-Aspartate","Excitatory Amino Acid Antagonists","Nootropic Agents"],"keywords":["Galantamine","Memantine","Medicine","Pharmacology","Acetylcholinesterase inhibitor","Dementia","Donepezil","Acetylcholinesterase","Rivastigmine","Clinical trial","Disease","Internal medicine","Biology","Alzheimer's disease","Pet Tracers","Major Neurocognitive Disorder","Aducanumab","Kat Ii Inhibitor"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T22:27:14.925001Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}